No Data
Express News | Gan & Lee Pharmaceuticals - Body Weight and Bmi Remain Below Baseline 21 Days Post-Treatment
Express News | Gan & Lee Pharmaceuticals - Gzr18 Tablets Show No Unexpected Safety Signals in Study
Express News | Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist Gzr18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks
Gan & Lee Pharmaceuticals (603087.SH): Xute Hongda plans to reduce its shareholding by no more than 1%.
On November 5, Gelonhui announced that gan & lee pharmaceuticals (603087.SH) stated that within 3 months after the expiration of 15 trading days from the date of this announcement, Xute Hongda plans to reduce its shareholding in a total of 6,010,652 shares through centralized auction trading, not exceeding 1% of the total share capital of the company.
Gan & Lee Pharmaceuticals (SHSE:603087) Is Posting Healthy Earnings, But It Is Not All Good News
Gan & Lee Pharmaceuticals Doses First Patient in Psoriasis Drug Trial
Gan & Lee Pharmaceuticals. (SHSE:603087) May Have Run Too Fast Too Soon With Recent 30% Price PlummetNo Data
No Data
